2. Immunology/Inflammation NF-κB Apoptosis Protein Tyrosine Kinase/RTK Anti-infection
  3. COX NF-κB TNF Receptor Interleukin Related Apoptosis VEGFR Bacterial Dengue Virus Caspase
  4. 4-Methoxycinnamic acid ethyl ester

4-Methoxycinnamic acid ethyl ester  (Synonyms: Ethyl p-methoxycinnamate)

Cat. No.: HY-N0346 Purity: 98.72%
COA
Handling Instructions Technical Support

4-Methoxycinnamic acid ethyl ester (Ethyl p-methoxycinnamate) is an orally active natural compound found. 4-Methoxycinnamic acid ethyl ester exerts anti-inflammatory effects by inhibiting cyclooxygenase (COX-1 (IC50 = 1.12 μM) and COX-2 (IC50 = 0.83 μM)), NF-κB (IC50 = 88.7 μM) and cytokine production (TNF-α (IC50 = 96.84 μg/mL) and IL-1β (IC50 = 166.4 μg/mL)). 4-Methoxycinnamic acid ethyl ester inhibits tumor cell proliferation, migration and cancer metabolism and induces apoptosis.4-Methoxycinnamic acid ethyl ester inhibits VEGF expression, thereby inhibiting angiogenesis. 4-Methoxycinnamic acid ethyl ester has a significant inhibitory effect on dengue virus and Mycobacterium tuberculosis. 4-Methoxycinnamic acid ethyl ester has analgesic effects in rats.

For research use only. We do not sell to patients.

4-Methoxycinnamic acid ethyl ester

4-Methoxycinnamic acid ethyl ester Chemical Structure

CAS No. : 1929-30-2

Size Price Stock Quantity
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg Get quote
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other Forms of 4-Methoxycinnamic acid ethyl ester:

4-Methoxycinnamic acid ethyl ester Related Antibodies

Top Publications Citing Use of Products

View All COX Isoform Specific Products:

View All Isoforms
COX COX-1 COX-2 COX-3

View All NF-κB Isoform Specific Products:

View All Isoforms
NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

View All TNF Receptor Isoform Specific Products:

View All Isoforms
TNFRSF1A/CD120a TNFRSF3/CD18 TNFRSF4 TNFRSF5/CD40 TNFRSF6/Fas/CD95 TNFRSF7/CD27 TNFRSF8/CD30 TNFRSF9/4-1BB/CD137 TNFRSF10B/DR5/CD262 TNFRSF12A/TWEAK TNFRSF16/NGF Receptor/CD271 TNFRSF18/GITR/CD357

View All Interleukin Related Isoform Specific Products:

View All Isoforms
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22 IL-18

View All VEGFR Isoform Specific Products:

View All Isoforms
VEGFR1/Flt-1 VEGFR2/KDR/Flk-1 VEGFR3/Flt-4

View All Caspase Isoform Specific Products:

View All Isoforms
Caspase 1 Caspase 2 Caspase 3 Caspase 4 Caspase 5 Caspase 6 Caspase 7 Caspase 8 Caspase 9 Caspase 10 Caspase 12 Caspase Caspase 11 Caspase-13

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

4-Methoxycinnamic acid ethyl ester (Ethyl p-methoxycinnamate) is an orally active natural compound found. 4-Methoxycinnamic acid ethyl ester exerts anti-inflammatory effects by inhibiting cyclooxygenase (COX-1 (IC50 = 1.12 μM) and COX-2 (IC50 = 0.83 μM)), NF-κB (IC50 = 88.7 μM) and cytokine production (TNF-α (IC50 = 96.84 μg/mL) and IL-1β (IC50 = 166.4 μg/mL)). 4-Methoxycinnamic acid ethyl ester inhibits tumor cell proliferation, migration and cancer metabolism and induces apoptosis.4-Methoxycinnamic acid ethyl ester inhibits VEGF expression, thereby inhibiting angiogenesis. 4-Methoxycinnamic acid ethyl ester has a significant inhibitory effect on dengue virus and Mycobacterium tuberculosis. 4-Methoxycinnamic acid ethyl ester has analgesic effects in rats[1][2][3][4][5][6][7].

IC50 & Target[1][2][7]

COX-1

1.12 μM (IC50)

COX-2

0.83 μM (IC50)

NF-κB

88.7 μM (IC50)

IL-1β

116.4 μg/mL (IC50)

Caspase-3

 

Caspase-7

 

Caspase-8

 

Caspase-9

 

Cellular Effect
Cell Line Type Value Description References
A-375 IC50
31.29 μM
Compound: 6
Cytotoxicity against human A375 cells by MTT assay
Cytotoxicity against human A375 cells by MTT assay
[PMID: 19782567]
HL-60 IC50
29.64 μM
Compound: 6
Cytotoxicity against human HL60 cells by MTT assay
Cytotoxicity against human HL60 cells by MTT assay
[PMID: 19782567]
THP-1 IC50
33.52 μM
Compound: 6
Cytotoxicity against human THP1 cells by MTT assay
Cytotoxicity against human THP1 cells by MTT assay
[PMID: 19782567]
In Vitro

4-Methoxycinnamic acid ethyl ester (25-200 μg/mL, 0-48 h) inhibits the growth of HUVECs with an IC50 of 160 μg/mL and suppresses the migration ability of HUVECs through VEGF[2].
4-Methoxycinnamic acid ethyl ester (50-200 μg/mL, 6-24 h) dose-dependently impairs the ability of HUVECs to form tube-like structures on Matrigel[2].
4-Methoxycinnamic acid ethyl ester (50-200 μg/mL, 5 d) significantly inhibits the sprouting and growth of microvessels from rat aortic rings[2].
4-Methoxycinnamic acid ethyl ester (0.03-0.97 mM, 7 d) inhibits M. tuberculosis H37Ra, H37Rv, drug susceptible and multidrug resistant (MDR) clinical isolates (MIC: 0.242-0.485 mM) and is ineffective against common bacteria such as Mycobacterium smegmatis, Escherichia coli, and Staphylococcus aureus[3].
4-Methoxycinnamic acid ethyl ester (50 μM, 12 h) significantly reduces the phosphorylation levels of p-p65 (Ser536) and p-Akt (Ser473) in melanoma cells[4].
4-Methoxycinnamic acid ethyl ester (50 μM, 24 h) significantly inhibits the migration and invasion ability of melanoma cells[4].
4-Methoxycinnamic acid ethyl ester (1-50 μM, 12-24 h) reverses the resistance of melanoma cells to Paclitaxel (HY-B0015)[4].
4-Methoxycinnamic acid ethyl ester (125-500 μM, 24 h) exhibits broad-spectrum antiviral activity against all four dengue serotypes (DENV-1, DENV-2, DENV-3, DENV-4), with EC50 values of 22.58 and 6.17 μM for DENV-2 in HepG2 and A549 cells, respectively[5].
4-Methoxycinnamic acid ethyl ester (100 μM, 1-24 h) inhibits de novo fatty acid synthesis, rather than glycolysis, to deplete ATP in ehrlich ascites cancer cells (EATCs)[6].
4-Methoxycinnamic acid ethyl ester (48 h) shows moderate cytotoxicity against MCF-7, HT-29, HCT-116 (IC50 = 42.1 μg/mL), U-937, PC-3 (IC50 = 39 μg/mL), K-562 cells[7].
4-Methoxycinnamic acid ethyl ester (50-200 μg/mL, 12-48 h) inhibits cell migration and induces apoptosis via the mitochondrial pathway in HCT-116 cells[7].
4-Methoxycinnamic acid ethyl ester (200 μg/mL, 8 h) significantly activates all tested caspases, including Caspase-9, Caspase-8, and Caspase-3/7 in HCT-116 cells[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

4-Methoxycinnamic acid ethyl ester Related Antibodies

Cell Migration Assay [2]

Cell Line: HUVECs
Concentration: 50, 100, 200 μg/mL
Incubation Time: 0, 6 and 12 h
Result: Effectively prevented the migration of endothelial cells to the damaged area.

Western Blot Analysis[4]

Cell Line: B16F10 G5-Luc and SK-Mel 28
Concentration: 50 μM
Incubation Time: 12 h (B16F10 G5-Luc) and 24 h (SK-Mel 28)
Result: Significantly reduced the phosphorylation levels of p-p65 (Ser536) and p-Akt (Ser473).
Upregulated the expression of γ-H2AX with Paclitaxel.

Cell Migration Assay [4]

Cell Line: B16F10 G5-Luc
Concentration: 50 μM
Incubation Time: 12 h
Result: Significantly inhibited the migration.

Cell Invasion Assay[4]

Cell Line: B16F10 G5-Luc
Concentration: 50 μM
Incubation Time: 12 h
Result: Significantly reduced the number of cells passing through Matrigel.

Western Blot Analysis[4]

Cell Line: 143B cells
Concentration: 2.5 μM
Incubation Time: 1, 2, 4, 8, 16 and 24 h
Result: Activated caspases and increased PARP-1 cleavage.
Promoted the phosphorylation of p53, and upregulated PUMA and Bax.
Increased the level of γH2AX.

RT-PCR[6]

Cell Line: EATCs
Concentration: 100 μM
Incubation Time: 1, 6 and 12 h
Result: Significantly downregulated the mRNA expression of key enzymes in fatty acid synthesis, including Acly, Acc1, and Fasn.
Was no significant effect on the mRNA expression of key fatty acid oxidation enzymes Cpt1a and Cpt1b.
Significantly downregulated the expression levels of SREBP1 mRNA.

Western Blot Analysis[6]

Cell Line: EATCs
Concentration: 100 μM
Incubation Time: 1, 6 and 12 h
Result: Significantly reduced the phosphorylation level of c-Myc protein Ser62 site.
Downregulated the expression of key enzymes in fatty acid synthesis (Acly, Acc1, Fasn).

Apoptosis Analysis[7]

Cell Line: HCT-116
Concentration: 50, 100, 200 μg/mL
Incubation Time: 48 h
Result: Dose-dependently induced chromatin condensation in HCT-116 cells.
Dose-dependent lost mitochondrial membrane potential.
In Vivo

4-Methoxycinnamic acid ethyl ester (100-800 mg/kg, i.g., single dose) inhibited paw edema in a dose-dependent manner in rats[4].
4-Methoxycinnamic acid ethyl ester (200-800 mg/kg, i.g., once daily for 7 days) inhibits the formation of chronic granuloma in a dose-dependent manner in rats[2].
4-Methoxycinnamic acid ethyl ester (200-800 mg/kg, i.g., single dose) prolongs the tail-flick latency of rats in a dose-dependent manner, showing a significant analgesic effect[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Carrageenan-induced paw edema model established in male Sprague Dawely (SD) rats (150-200 g)[1]
Dosage: 100, 200, 400 and 800 mg/kg
Administration: Oral gavage (i.g.), single dose
Result: Inhibited paw edema in a dose-dependent manner, with the minimum effective dose (MIC) being 100 mg/kg.
No toxic reactions were observed at 2000 mg/kg.
Animal Model: Cotton pellet granuloma assay established in male Sprague Dawely (SD) rats (200-250 g)[2]
Dosage: 200, 400, 800 mg/kg
Administration: Oral gavage (i.g.), once daily for 7 days
Result: Reached inhibition rate by 51.65% at 800 mg/kg.
Inhibited the production of key pro-inflammatory cytokines IL-1β and TNF-α.
Animal Model: Tail flick assay established in male Sprague Dawely (SD) rats (200-250 g)[2]
Dosage: 200, 400, 800 mg/kg
Administration: Oral gavage (i.g.), single dose
Result: Prolonged the tail-flick latency of rats in a dose-dependent manner
Molecular Weight

206.24

Formula

C12H14O3
CAS No.
Appearance

Solid

SMILES

O=C(OCC)/C=C/C1=CC=C(OC)C=C1
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (484.87 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 4.8487 mL 24.2436 mL 48.4872 mL
5 mM 0.9697 mL 4.8487 mL 9.6974 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (12.12 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: 2.5 mg/mL (12.12 mM); Suspended solution; Need ultrasonic

    This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 98.72%

COA (244 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 4.8487 mL 24.2436 mL 48.4872 mL 121.2180 mL
5 mM 0.9697 mL 4.8487 mL 9.6974 mL 24.2436 mL
10 mM 0.4849 mL 2.4244 mL 4.8487 mL 12.1218 mL
15 mM 0.3232 mL 1.6162 mL 3.2325 mL 8.0812 mL
20 mM 0.2424 mL 1.2122 mL 2.4244 mL 6.0609 mL
25 mM 0.1939 mL 0.9697 mL 1.9395 mL 4.8487 mL
30 mM 0.1616 mL 0.8081 mL 1.6162 mL 4.0406 mL
40 mM 0.1212 mL 0.6061 mL 1.2122 mL 3.0304 mL
50 mM 0.0970 mL 0.4849 mL 0.9697 mL 2.4244 mL
60 mM 0.0808 mL 0.4041 mL 0.8081 mL 2.0203 mL
80 mM 0.0606 mL 0.3030 mL 0.6061 mL 1.5152 mL
100 mM 0.0485 mL 0.2424 mL 0.4849 mL 1.2122 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

4-Methoxycinnamic acid ethyl ester Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

4-Methoxycinnamic acid ethyl ester1929-30-2Ethyl p-methoxycinnamateCOXNF-κBTNF ReceptorInterleukin RelatedApoptosisVEGFRBacterialDengue VirusCaspaseCyclooxygenaseNuclear factor-κBNuclear factor-kappaBTumor Necrosis Factor ReceptorTNFRILVascular endothelial growth factor receptorDENVKampferia galangaethyl p-methoxycinnamate (EPMC)p38αphospho-Akt (Ser473)NFκBB16F10-NFκB Luc2chemosensitizeranti-metastasisInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
4-Methoxycinnamic acid ethyl ester
Cat. No.:
HY-N0346
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.